J Drugs Dermatol. 2021 Jan 1;20(1):31-37. doi: 10.36849/JDD.5617.
Treatment of upper facial lines is a common aesthetic practice; however, there is limited information on systematic tailored approaches for the treatment of forehead wrinkles using botulinum toxin A.
To describe the safety and efficacy of the ONE21 technique using incobotulinumtoxinA (INCO) for the treatment of forehead wrinkles.
Single-center, retrospective study with 86 females presenting a baseline Merz Aesthetic Scale (MAS) score ≥2 for dynamic forehead lines who had been treated with INCO using the ONE21 technique. Assessment was performed by two independent blinded raters using MAS for forehead lines (dynamic and at rest), and eyebrow positioning, based on standardized pictures taken before (baseline) and 4 (±2) weeks after treatment injection. The primary outcome was the percentage of subjects with a MAS improvement ≥2 points for dynamic forehead lines at week 4 (±2). Secondary outcomes were MAS scores for resting forehead lines and for eyebrow positioning.
The mean age was 46.2 years, and mean total dose of INCO, 20.3 U. Most (97.7%) subjects had a MAS improvement of ≥2 points for dynamic forehead lines at week 4 (±2); 100% improved ≥1 point. MAS scores for resting and dynamic lines, and eyebrow positioning were significantly improved (P<0.001). Eyebrow positioning MAS improved ≥1 point in 56.9% of subjects, and 39.5% maintained the original shape.
INCO injection using the ONE21 technique is effective and safe in treating forehead wrinkles, providing a natural result, with a customized treatment and a predictable eyebrow shape. J Drugs Dermatol. 2021;20(1):31-37. doi:10.36849/JDD.5617.
治疗上面部线条是一种常见的美容实践；然而，关于使用肉毒毒素 A 系统地针对额部皱纹进行定制治疗的信息有限。
描述使用 incobotulinumtoxinA（INCO）治疗额部皱纹的 ONE21 技术的安全性和有效性。
单中心、回顾性研究，86 名女性出现基线 Merz 美学量表（MAS）评分 ≥2，表现为动态额部线条，使用 ONE21 技术用 INCO 治疗。评估由两名独立的盲法评分员使用 MAS 进行，用于额部线条（动态和休息时）和眉毛位置，基于治疗注射前（基线）和 4（±2）周后拍摄的标准化照片。主要结局是第 4（±2）周时动态额部线条 MAS 改善 ≥2 分的受试者比例。次要结局是休息时额部线条和眉毛位置的 MAS 评分。
平均年龄为 46.2 岁，INCO 总剂量为 20.3U。大多数（97.7%）患者在第 4（±2）周时动态额部线条的 MAS 改善 ≥2 分；100%改善 ≥1 分。休息和动态线条以及眉毛位置的 MAS 评分均显著改善（P<0.001）。56.9%的患者眉毛位置 MAS 改善 ≥1 分，39.5%保持原有形状。
使用 ONE21 技术的 INCO 注射治疗额部皱纹有效且安全，可提供自然的治疗效果，具有定制化的治疗方案和可预测的眉毛形状。J 皮肤病药物学杂志。2021；20（1）：31-37。doi:10.36849/JDD.5617.
